Combinations of various Vertex drugs could benefit 90% of cystic fibrosis patients.
In a bubbly year for the biotech sector, these five stocks stand out over the rest.
Monsanto gained Monday after a U.S. appeals court dismissed a lawsuit filed by organic farmers.
Ampio attacks critics instead of answering legitimate questions.
Drugs from Gilead Sciences and Roche stood out at ASCO this year, while Infinity's drug lagged.
Biotech columnist Adam Feuerstein answers readers' questions about healthcare companies.
Amarin's president says company is preparing for FDA advisory panel seeking expansion of fish-oil pill's use.
Aveo's next chance to resurrect its flailing cancer drug will come in 2014/2015 with breast cancer study data.
Successful combination therapy is the key to growing Vertex's cystic fibrosis business to blockbuster status.
The failure of a kidney cancer drug won't stop Aveo executives from cashing future paychecks.
Surprisingly strong results for a lung cancer drug have helped Clovis double in value today.
A narrowing of the survival benefit plus competition from anti-PD1s makes Synta's ganetespib success a long shot.
The anti-PD-1s are shrinking tumors like no drugs have done before and investors are really excited.
Charting the drug and biotech stocks which came out ahead at this weekend's ASCO annual meeting, and those that fell behind.
More evidence that immune system-boosting drugs are changing the way melanoma is treated.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV